INKT
Price:
$0.4912
Market Cap:
$19.43M
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.[Read more]
Industry
Biotechnology
IPO Date
2021-10-15
Stock Exchange
NASDAQ
Ticker
INKT
According to MiNK Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.89. This represents a change of 32.74% compared to the average of 0.67 of the last 4 quarters.
The mean historical Current Ratio of MiNK Therapeutics, Inc. over the last ten years is 0.95. The current 0.89 Current Ratio has changed 9.27% with respect to the historical average. Over the past ten years (40 quarters), INKT's Current Ratio was at its highest in in the December 2021 quarter at 2.41. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
0.95
Median
0.32
Minimum
0.12
Maximum
2.41
Discovering the peaks and valleys of MiNK Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 735.68%
Maximum Annual Current Ratio = 2.41
Minimum Annual Increase = -80.38%
Minimum Annual Current Ratio = 0.12
Year | Current Ratio | Change |
---|---|---|
2023 | 0.32 | -80.38% |
2022 | 1.61 | -33.17% |
2021 | 2.41 | 735.68% |
2020 | 0.29 | 132.69% |
The current Current Ratio of MiNK Therapeutics, Inc. (INKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.44
5-year avg
0.95
10-year avg
0.95
MiNK Therapeutics, Inc.’s Current Ratio is less than Affimed N.V. (1.93), less than ImmunoGen, Inc. (5.47), less than Adaptimmune Therapeutics plc (3.85), less than Sangamo Therapeutics, Inc. (1.35), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (10.43), less than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than VectivBio Holding AG (9.14), less than Terns Pharmaceuticals, Inc. (32.99), less than HOOKIPA Pharma Inc. (3.26), greater than Kineta, Inc. (0.14), less than Candel Therapeutics, Inc. (1.18), less than Forte Biosciences, Inc. (2.06), less than AlloVir, Inc. (86.78), less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), less than Stoke Therapeutics, Inc. (5.09),
Company | Current Ratio | Market cap |
---|---|---|
1.93 | $18.12M | |
5.47 | $8.73B | |
3.85 | $150.46M | |
1.35 | $498.67M | |
14.62 | $1.28B | |
10.43 | $106.34M | |
4.89 | $98.42M | |
7.68 | $193.36M | |
9.14 | $1.06B | |
32.99 | $503.69M | |
3.26 | $19.60M | |
0.14 | $7.05M | |
1.18 | $383.82M | |
2.06 | $27.79M | |
86.78 | $52.01M | |
6.03 | $438.66M | |
34.61 | $351.62M | |
10.10 | $69.96M | |
15.32 | $80.59M | |
5.09 | $614.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MiNK Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MiNK Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is MiNK Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for MiNK Therapeutics, Inc. (INKT)?
What is the highest Current Ratio for MiNK Therapeutics, Inc. (INKT)?
What is the 3-year average Current Ratio for MiNK Therapeutics, Inc. (INKT)?
What is the 5-year average Current Ratio for MiNK Therapeutics, Inc. (INKT)?
How does the current Current Ratio for MiNK Therapeutics, Inc. (INKT) compare to its historical average?